A slump in sales due to COVID-19, a significant reorientation of strategy in Japan, continued pressures over US investigations into price-fixing, a major biosimilars deal and a key new respiratory launch meant there was plenty to talk about during Teva’s presentation of its second-quarter results this week.
“During the quarter, we experienced lower sales of our generic and OTC products in all regions,” acknowledged Teva’s president and...